The Launch and Uptake of Nine Emerging Therapies Will Drive the
Prostate Cancer Drug Market to More Than Double to $8.4 Billion in
2019
20 July 2010
Decision Resources, Inc
Emerging Therapies, Most Notably Dendreon's Provenge, Will
Account For More Than Half of the Total Prostate Cancer Market in
2019, According to Findings from Decision Resources
WALTHAM, Mass., July 20 /PRNewswire/ -- Decision Resources, one
of the world's leading research and advisory firms for
pharmaceutical and healthcare issues, finds that the launch and
uptake of nine emerging therapies will drive the prostate cancer
drug market to more than double from nearly $4 billion in 2009 to
$8.4 billion in 2019 in the United States, France, Germany, Italy,
Spain, the United Kingdom and Japan.
Full article
DISCLAIMER
The links and content above are provided for your convenience to provide further information and do not constitute an endorsement by Bavarian Nordic. We have no control over the nature, content and availability of the sites that are being linked to and thus we assume no responsibility for the privacy practices on such websites.
